All studies
Endocrinology · EHR · United Kingdom
Wang 2026
Type 2 diabetes
ITT and as-treatedSuperiorityAcademia, Industry2/5 disclosures
Comparisons
3
In the analysis
1
2 withheld
Target trials
1
Emulations reported
3
2 treatments
Design and methods
- Estimand
- ITT and as-treated
- Design hypothesis
- Superiority
- Matching / weighting
- Propensity-score weighting
- Analysis method
- Weighted Cox proportional hazards model
- Missing data
- Multiple imputation
- DAG
- No
- QBA
- No
Data and sample
- Data type
- EHR
- Data sources
- CPRD linked to hospital data
- Geography
- United Kingdom
- Eligible sample
- 10430
- Treated
- 812
- Control
- 9618
- Emulations
- 3
- Treatments compared
- 2
Transparency
- Protocol
- No pre-registration
- Preprint
- No preprint
- Data availability
- Unavailable
- Code availability
- Unavailable
- Conflicts of interest
- Declared: Industry
- COI institutions
- Amgen and other disclosed relationships
- Funding
- Declared: Public
- Funders
- Canadian Institutes of Health Research; Fonds de recherche du Québec
The 0-5 count records which disclosures are present. It is not a quality score: a data link does not establish that the data are reusable.
Provenance
- Review key
- 2026_Wang_DEVOTE
- DOI
- https://doi.org/10.1002/pds.70313
- Affiliations
- McGill University and collaborating Canadian and UK institutions
- Sector
- Academia, Industry
- Target trials (study level)
- DEVOTE
- Registration
- NCT01959529